Thanks, brick. The 2013 conference call had questi

Thanks, brick. The 2013 conference call had question by Jason Napadano concerning the LymPro licensing from Provista. There is the potential for new investors to get caught up in the negative logic that this asset with the revenue potential claimed by Amarantus couldn't have been obtained so cheaply. Gerald's response to Jason's question blows this negative logic out of the water, and provides the most complete account of the circumstances surrounding the LymPro acquisition that is available to shareholders.

In case anyone misses my pet elephant Ollie (short for Oliver), enjoy! It's hard to imagine any sane person getting upset over me having a pet elephant. LOL

The truth is incontrovertible. Malice may attack it, ignorance may deride it, or a narcissistic board moderator may delete it because it doesn't support his disjointed thinking, but in the end, there it is.
   – Windbag Duckbill